ARCHIVES

Tamoxifin Benefits Outweigh Risks, NSABP Study Finds

This article is from The Cancer Letter archive.

Vol. 20 No. 12 | March 23, 1994

Download PDF Visit The Full Archive

Related Articles

Pooled Analysis of Two LUX-Lung Trials Shows Prolonged Survival with Afatinib

June 27, 2014

In Brief: William Roper To Head Health Research Center; Announcement Of New NIH director Is Imminent

July 2, 1993

Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says

October 2, 1992

Bills in House, Senate, would give FDA authority over tobacco products.

June 4, 2004

Abstract Of Papers Presented By Breast Cancer Task Force

September 24, 1976

FDA Puts Clinical Hold On Gene Therapy Trials

January 24, 2003